Outlook Therapeutics® to Report Financial Results for Third Quarter Fiscal Year 2024 on August 14, 2024 and Host Quarterly Conference Call and Webcast
Outlook Therapeutics (Nasdaq: OTLK), a biopharmaceutical company that has received regulatory approval in the EU and UK for the first authorized ophthalmic formulation of bevacizumab to treat wet AMD, has announced its upcoming financial results release. The company will report its third quarter fiscal year 2024 results on Wednesday, August 14, 2024. Following the release, management will host a conference call and live audio webcast at 8:30 AM ET to discuss operational and financial outcomes.
The call will be led by Russell Trenary, President and CEO, and Lawrence Kenyon, CFO. Investors can join the call by dialing (877) 407-8291 (domestic) or (201) 689-8345 (international). A live webcast will also be available on the company's website and archived for 90 days.
Outlook Therapeutics (Nasdaq: OTLK), un'azienda biofarmaceutica che ha ricevuto l'approvazione normativa nell'UE e nel Regno Unito per la prima formulazione oftalmica autorizzata di bevacizumab per trattare l'AMD umido, ha annunciato la prossima pubblicazione dei suoi risultati finanziari. L'azienda riporterà i risultati del terzo trimestre dell'anno fiscale 2024 mercoledì 14 agosto 2024. Dopo la pubblicazione, il management terrà una conferenza telefonica e una diretta audio a 8:30 AM ET per discutere i risultati operativi e finanziari.
La chiamata sarà guidata da Russell Trenary, Presidente e CEO, e Lawrence Kenyon, CFO. Gli investitori possono partecipare alla chiamata componendo il numero (877) 407-8291 (nazionale) o (201) 689-8345 (internazionale). Sarà inoltre disponibile una diretta streaming sul sito web dell'azienda e archiviata per 90 giorni.
Outlook Therapeutics (Nasdaq: OTLK), una empresa biofarmacéutica que ha recibido la aprobación regulatoria en la UE y el Reino Unido para la primera formulación oftálmica autorizada de bevacizumab para tratar la degeneración macular húmeda (AMD), ha anunciado la próxima publicación de sus resultados financieros. La compañía reportará sus resultados del tercer trimestre del año fiscal 2024 el miércoles 14 de agosto de 2024. Tras la publicación, la dirección llevará a cabo una conferencia telefónica y una transmisión de audio en vivo a las 8:30 AM ET para discutir los resultados operativos y financieros.
La llamada será liderada por Russell Trenary, Presidente y CEO, y Lawrence Kenyon, CFO. Los inversores pueden unirse a la llamada marcando el (877) 407-8291 (nacional) o el (201) 689-8345 (internacional). También habrá una transmisión en vivo disponible en el sitio web de la compañía y se archivará durante 90 días.
아웃룩 테라퓨틱스 (Nasdaq: OTLK)는 습성 황반변성을 치료하기 위해 유럽연합과 영국에서 최초로 승인된 베바시주맙의 안과용 조제에 대한 규제 승인을 받은 바이오 제약 회사로, 다가오는 재무 결과 발표를 알렸습니다. 회사는 2024 회계연도 3분기 결과를 2024년 8월 14일 수요일에 보고할 예정입니다. 발표 후, 경영진은 운영 및 재무 결과에 대해 논의하기 위해 동부 표준시 8:30 AM에 컨퍼런스 콜 및 실시간 오디오 웹캐스트를 진행할 것입니다.
이 전화회의는 러셀 트레너, 사장 겸 CEO, 그리고 로렌스 켄욘, CFO가 이끌 것입니다. 투자자들은 (877) 407-8291 (국내) 또는 (201) 689-8345 (국제)로 전화하여 회의에 참여할 수 있습니다. 또한 회사 웹사이트에서 실시간 웹캐스트를 이용할 수 있으며, 90일 동안 보관됩니다.
Outlook Therapeutics (Nasdaq: OTLK), une entreprise biopharmaceutique qui a reçu l'approbation réglementaire dans l'UE et au Royaume-Uni pour la première formulation ophtalmique autorisée de bevacizumab pour traiter la DMLA humide, a annoncé la publication prochaine de ses résultats financiers. L'entreprise publiera ses résultats du troisième trimestre de l'exercice fiscal 2024 le mercredi 14 août 2024. Après la publication, la direction organisera une conférence téléphonique et un webinaire audio en direct à 8h30 ET pour discuter des résultats opérationnels et financiers.
La conférence sera dirigée par Russell Trenary, Président et PDG, et Lawrence Kenyon, CFO. Les investisseurs peuvent rejoindre la conférence en composant le (877) 407-8291 (national) ou le (201) 689-8345 (international). Un webinaire en direct sera également disponible sur le site Web de l'entreprise et archivé pendant 90 jours.
Outlook Therapeutics (Nasdaq: OTLK), ein biopharmazeutisches Unternehmen, das in der EU und im Vereinigten Königreich die behördliche Genehmigung für die erste zugelassene ophthalmologische Formulierung von Bevacizumab zur Behandlung von feuchter AMD erhalten hat, hat die bevorstehende Veröffentlichung seiner Finanzergebnisse bekannt gegeben. Das Unternehmen wird seine Ergebnisse für das dritte Quartal des Geschäftsjahres 2024 am Mittwoch, den 14. August 2024, bekannt geben. Im Anschluss an die Veröffentlichung wird das Management eine Telefonkonferenz und ein Live-Audio-Webcast um 8:30 Uhr ET abhalten, um die operativen und finanziellen Ergebnisse zu erörtern.
Die Konferenz wird von Russell Trenary, Präsident und CEO, sowie Lawrence Kenyon, CFO, geleitet. Anleger können an der Konferenz teilnehmen, indem sie (877) 407-8291 (inland) oder (201) 689-8345 (aus dem Ausland) anrufen. Ein Live-Webcast wird auch auf der Unternehmenswebsite verfügbar sein und für 90 Tage archiviert.
- Regulatory approval obtained in EU and UK for ophthalmic bevacizumab formulation for wet AMD treatment
- None.
ISELIN, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that has achieved regulatory approval in the EU and UK for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet AMD, today announced that it will report its financial results for third quarter fiscal year 2024 on Wednesday, August 14, 2024. Outlook Therapeutics management will host its quarterly conference call and live audio webcast to discuss the operational and financial results at 8:30 AM ET that same day.
The call will be led by Russell Trenary, President and Chief Executive Officer and Lawrence Kenyon, Chief Financial Officer of Outlook Therapeutics. Interested participants and investors may access the conference call by dialing (877) 407-8291 (domestic) or (201) 689-8345 (international) and referencing the Outlook Therapeutics Conference Call. The live webcast will be accessible on the Events page of the Investors section of the Outlook Therapeutics website, outlooktherapeutics.com, and will be archived for 90 days.
About Outlook Therapeutics, Inc.
Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma), for the treatment of retina diseases, including wet AMD. LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and United Kingdom Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics is working to initiate its commercial launch of LYTENAVA™ (bevacizumab gamma) in the EU and the UK as a treatment for wet AMD in the first calendar quarter of 2025. In the United States, ONS-5010/LYTENAVA™ is investigational, is being evaluated in an ongoing non-inferiority study for the treatment of wet AMD, and if successful, the data may be sufficient for Outlook to resubmit a BLA application to the FDA in the United States. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD. For more information, please visit www.outlooktherapeutics.com.
Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 833.475.8247
OTLK@jtcir.com
FAQ
When will Outlook Therapeutics (OTLK) report its Q3 FY2024 financial results?
What time is Outlook Therapeutics' (OTLK) Q3 FY2024 earnings call scheduled?
Who will lead Outlook Therapeutics' (OTLK) Q3 FY2024 earnings call?
What regulatory approvals has Outlook Therapeutics (OTLK) received for its bevacizumab formulation?
